Approval · Notice of Compliance 12897 · 2011
MEMANTINE: Notice of Compliance 12897
Issued December 21, 2011
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 12897
- Date
- December 21, 2011
- Company
- Meliapharm IncMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Removal of commitments as per the Letter of Undertaking dated March 23, 2010 for the symptomatic treatment of patients with moderate to severe dementia of the Alzheimer's type
- Therapeutic class
- N-methyl-D-aspartate receptor antagonist
- Canadian reference product
- EBIXA (Lundbeck Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MEMANTINE | Not yet assigned | — |
Medicinal ingredients
- MEMANTINE HYDROCHLORIDE 10 MG per TAB